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PHOTOCLEAVABLE LINKER FOR PROTEIN AFFINITY LABELING TO IDENTIFY THE
BINDING TARGET OF KCN-1

by

HANG T. TRAN

Under the Direction of Binghe Wang

ABSTRACT

KCN-1 is known to reduce tumor growth 6-fold in mice implanted with LN229 glioma
cells. Although this inhibitor is effective, the mechanism of action for KCN-1 is not well
understood. Based on preliminary studies, KCN-1 reduces tumor growth by disrupting the
HIF-1 (hypoxia-induced factor-1) pathway.

The binding target of KCN-1 needs to be

investigated in order to develop KCN-1 or its analogs for therapeutic applications. In this
research, a molecule was designed and synthesized for the identification of the binding target of
KCN-1. Specifically, this molecule contains the inhibitor (KCN-1), a photocleavable linker,

beads, and the affinity label (L-DOPA). When UV light shines on the linker, the trans-alkene
isomerizes to cis-alkene and undergoes intramolecular ring-closing reaction, which helps cleave
the immobilized bead from the linker. The immobilized bead is used to separate the binding
fragment attached to the photocleavable linker from the solution after enzyme digestion. The
affinity label (L-DOPA) reacts with a nucleophile from the binding target and creates a covalent
bond. If the design is successful, this method is able to analyze the mass of the peptide sequence
and determine the binding target of KCN-1.
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1.
1.1

INTRODUCTION

Hypoxia
Hypoxia is a condition of oxygen deprivation. When oxygen level decreases, an adaptive

response occurs that is mediated by hypoxia-inducible factor-1 (HIF-1)1.

HIF-1 activates

transcription of genes that help cells survive in low oxygen conditions. These genes code for
proteins that promote angiogenesis to form new blood vessels, glucose metabolism to provide
more energy, and cell proliferation.
Hypoxia commonly occurs in solid tumors because oxygen is limited in the interior of the
tumor mass2. The blood vessel is too far from the hypoxic area to deliver adequate amount of
oxygen. Thus, there is an increase of HIF-1 activity and stabilization in those areas. As a result,
the activation of genes helps solid tumor cells survive and expand. Hypoxia is a major driving
force of tumor progression because cells undergo adaptive genetic changes that prevent hypoxiainduced cell death and necrosis2.
1.2

HIF-1 Pathway
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that responds to changes in

oxygen and is up-regulated in hypoxia3. It is a heterodimeric protein that consists of HIF-1α and
HIF-1β subunits. HIF-1α is oxygen-sensitive consisting of an oxygen-dependent degradation
(ODD) domain. HIF-1β completes the heterodimeric protein and binds with HIF-1α for the
translocation to the nucleus.

CBP/p300

HIFHIF-

P N

2

Figure 1.1: A comparison of hypoxia-inducible factor-1 pathway in normoxia and
hypoxia4
Under normoxia, as shown in Figure 1.1, HIF-1α subunit has an exceptionally short
half-life because it is subjected to rapid turnover and degradation by the ubiquitin proteasome
pathway5.

Since oxygen is available, the oxygen-dependent degradation (ODD) domain

undergoes hydroxylation by prolyl hydoxylases (PHDs) and factor inhibiting HIF-1 (FIH-1).
The PHDs and FIH-1 are iron-dependent enzymes requiring oxygen to hydroxylate prolines and
asparagines, respectively, in the ODD domain. As a result of the hydroxylated prolines, the von
Hippel-Lindau protein (VHL) binds to the HIF-1α subunit, which leads to ubiquitination. Since
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the asparagines are hydroxylated, the transcription co-activator (CBP/p300) cannot bind to the
HIF-1α subunit, which leads to transcriptional repression.

Thus, transcriptional activity is

reduced and HIF-1α subunit undergoes proteasomal degradation.
Under hypoxic condition, as shown in Figure 1.1, HIF-1α subunit cannot be hydroxylated
because of decreased oxygen availability. This means that VHL cannot bind to HIF-1α subunit
and cannot lead to proteosomal degradation. HIF-1α subunit is abundant and binds to the
transcription co-activator (CBP/p300), which initiates the transcriptional activity. Then, HIF-1β
subunit binds to the HIF-1α subunit and the heterodimeric protein translocates to the nucleus for
the transcription of genes. These genes include erythropoiesis (Epo) to produce red blood cells,
vascular endothelial growth factor A (VEGF) to form more blood vessels, and glucose
metabolism (Glut1) to provide energy for cells5.
1.3

KCN-1 Inhibitor
HIF-1 is overly expressed in human cancer. Since more genes are expressed, as well as

altered, many tumors undergo genetic changes that facilitate adaptation and survival of the cells2.
Thus, these adaptations and genetic changes make tumor cells more resistance to conventional
treatments, such as chemotherapy2. Therefore, inhibition of HIF-1 leads to anti-tumor effects
and can be a target for drug development.
OMe

O

O
N S
O

OMe

Figure 1.2: Molecular structure of KCN-1.
The interest of finding small molecules that disrupt the HIF-1 pathway led to an inhibitor
known as KCN-1. KCN-1, shown in Figure 1.2, is a lead compound identified by screening a
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10,000 member combinatorial library from Nicolaou6. It was chosen for evaluation in Dr. Van
Meir’s laboratory at Emory University. Preliminary in vivo experiments of KCN-1 showed
significant anti-tumor activity. Nude mice were implanted with LN229 glioma tumor cells on
both hind flanks. After one week, one group of mice was injected with KCN-1 (60 mg/kg; 5
days/week) and the vehicle. The other group received the vehicle alone, the control. The mice
injected with KCN-1 showed 6-fold less in tumor mass than the control. Based on the results,
KCN-1 reduces and slows tumor growth. In addition, the KCN-1 injected mice displayed no
apparent signs of toxicity or other negative effects.
Although KCN-1 is a potent inhibitor that reduces tumor growth dramatically, the
binding target of KCN-1 is not known. However, there is evidence to support that KCN-1 binds
to component of the HIF-1 pathway. Based on other preliminary studies done in collaboration
with the Van Meir lab, KCN-1 may bind to transcription co-activator p300. This study was
performed by Oregon Green fluorophore modified KCN-1 for cell imaging. Although results
showed that KCN-1 binds to transcription co-activator p300, further experiments are needed to
confirm this mechanism of KCN-1 interacting in tumor cells. Therefore, protein affinity labeling
experiments will be used to identify the binding target of KCN-1.
1.4

Affinity Labeling
There are many techniques for tagging proteins. One of these techniques is affinity

labeling. This method uses the property of recognition between two different molecules to react
and form a chemical bond. It is widely used to identify proteins, localize binding sites, and
determine targets of drugs. The affinity label molecule binds specifically and reversibly to the
target protein7. However, when it is photo-activated or chemically activated, it forms a highly
reactive intermediate and reacts irreversibly with the nucleophilic residue of the target protein7.
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Figure 1.3: Kodadek laboratory’s novel type chemically activated molecule used to
determine the binding target of free ubiquitin8
In recent years, the Kodadek laboratory developed a novel type of chemically activated
molecule that formed an extremely reactive electrophilic intermediate. This method was used to
determine the binding target of free ubiquitin (Ub). The molecule contained ubiquitin tagged
with a biarsenical fluorescein derivative (F1AsH), a biotin moiety, and a catechol of the
dihydroxyphenylalanine (L-DOPA)8.

The most important aspect of this molecule was the

catechol of L-DOPA as shown in Figure 1.3. The catechol ring of the L-DOPA subunit can be
oxidized to an ortho-quinone selectively with sodium periodate (NaIO4)8. At close proximity
between the ubiquitin and its binding target protein, the electrophilic quinone intermediate reacts
with the nucleophilic residue of the protein8. The results showed that the proteasome function
was not affected by the chemical activator NaIO4. Since the Kodadek method was very effective
in their studies, it will be used for the affinity labeling work in this research. The affinity label
(L-DOPA) will be utilized to investigate the binding of KCN-1 to its target protein.
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1.5

Purpose of the Study

Figure 1.4:

Photocleavable linker attached to the immobilized bead, L-DOPA, and
KCN-1.

The purpose of this study is to design a small molecule that will identify the binding
target of KCN-1. Thus, the objective is to synthesize the molecule shown in Figure 1.4. This
molecule contains inhibitor KCN-1, a chemically activatable affinity label L-DOPA, the bead,
and a photocleavable linker.
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Figure 1.5: Proposed mechanism for the affinity label, L-DOPA, to covalently link to the
target protein.
The proposed mechanism of this project consists of KCN-1 binding to a protein at a
specific site. As mentioned above, the L-DOPA is the chemically activatable affinity label
molecule. It is used to form a covalent bond with the binding target. When the target protein
and the KCN-1 are closely associated, the chemical activator NaIO4 converts the catechol of LDOPA to a very reactive electrophile. As shown in Figure 1.5, sodium periodate (NaIO4)
oxidizes the catechol of L-DOPA to form 1,2-benzoquinone9. Thus, a nucleophile from the
receptor of the target protein reacts with this electrophilic quinone. This reaction converts the
quinone back to the catechol9. Overall, this procedure forms a covalent bond between the
affinity label molecule L-DOPA and the binding target.
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Figure 1.6: Proposed mechanism of the photocleavable linker.
After the protein undergoes enzyme digestion, as shown in Figure 1.6, the fragment
covalently bound to the photocleavable linker is pulled out through the use of the bead, which is
insoluble so it can easily separate from the solution and other fragments. The linker and
immobilized bead are cleaved from the rest of the molecule once separated from the solution.
This process occurs when UV light of 365 nm excites the trans-alkene, leading to isomerization
and formation of the cis-alkene10. The linker then undergoes intramolecular cyclization reaction.
The carbonyl, adjacent to the double bond carbon, reacts with the hydroxyl, on the aromatic ring,
to form a chromanone and cleaves the KCN-1, L-DOPA, and the residue covalently bond to the
10

L-DOPA

. Then, the covalently linked residue is analyzed through mass spectroscopy by ESI or

MALDI. The molecular weight is used to determine the sequence of the binding target. If the
design is successful, this method is able to analyze the mass of the binding sequence and identify
the target protein.
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Figure 1.7: The retrosynthetic analysis of the photocleavable linker.
The retrosynthesis of the photocleavable linker is shown in Figure 1.7. Amidation is the
key component, which makes this synthetic route possible. Deprotection of Boc- and MOMgroup make it possible for the amidation with the immobilized bead. Compound 11 is formed by
reacting KCN-1 free amine 12d and carboxylic acid of the L-DOPA 10. The L-DOPA fragment
is commercially available and is added by yet another amidation with the linker 8.
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2.
2.1

DISCUSSION

Synthesis of Compound 11
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Scheme 1. Synthetic route of compound 11
The synthesis of the photocleavable linker was accomplished in 3.6% overall yield, as
shown in Scheme 1.

The first step was the iodination of commercially available

m-hydroxybenzoic acid 1 by the use of iodine and potassium iodide in aqueous ammonia. The
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aromatic carboxylic acid 2 was reduced with borane in tetrahydrofuran to generate primary alkyl
benzylic alcohol 3. Protection of the hydroxyl was needed for the conversion of the alcohol 4 to
azide 5. Thus, the hydroxyl on the aromatic ring 3 was protected with chloromethyl methyl ether
(MOMCl).

The next step was azidation of the primary alkyl benzylic alcohol 4 using

diphenylphosphoryl azide (DPPA) in the presence of strong organic base diazabicycloundecane
(DBU). This reaction was preceded by O-phosphorylation followed by SN2 displacement to
generate the azide compound 5. This compound was reduced to amine by a mild method of
Staudinger reaction, which used triphenylphosphine as the reducing agent11. The final reaction
yielded triphenylphosphine oxide as the side product and the amine compound 6. The amine
needed to be preserved for the attachment with the bead at the end. Thus, the Boc-protected
compound 7 was generated using di-tert-butyl dicarbonate in the presence of base triethylamine
in methanol. The next step was to create the photochemical esterase. This step was a simple
Heck reaction using palladium catalyze carbon-carbon coupling between aryl iodide and
activated alkene, acrylic acid, in the presence of K2CO3 base12. The carboxylic acid 8 was
activated

with

N-hydroxysuccinimide

(NHS)

and

coupling

reagent

1-ethyl-3-(3-

dimethylaminopropyl) carbodiimide) (EDCI) in dichloromethane (DCM). The activated ester 9
reacted with commercially available (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(L-DOPA) and triethylamine in DMF to generate compound 10. Compound 11 was successfully
synthesized by amidation of compound 10 with KCN-1 amine 12d in the presence of coupling
agents EDCI and hydroxybenzotriazole (HOBt). The final protected compound 11 was purified
by HPLC.
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2.2

Synthesis of KCN-1 amine 12d

O
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Scheme 2. Synthetic route of compound 12d (KCN-1 amine).
The KCN-1 amine 12d was synthesized as shown in Scheme 2. The KCN-1 12a was
made available by the Van Meir Laboratory at Emory University. The methoxy on the paraposition was selectively demethylated with thiophenol and K2CO3 base in N-Methyl-2pyrrolidone (NMP) at temperature of 150 ºC. The time was extremely important because if the
reaction ran more than five minutes, the methoxy on the meta-position would be demethylated
also. Then the hydroxyl compound 12b was alkylated with N-(4-bromobutyl) phthalimide and
K2CO3 base in dimethylformamide (DMF). The phthalimide KCN-1 12c was reduced to the
final KCN-1 amine 12d by refluxing with hydrazine in a mixture of ethanol and
dichloromethane.
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2.3

Approaches to Compound 13
MOM O
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10%TFA in DCM
rt, 10min

N
H

H 2N

R

MOM- not deprotected
1 drop concentrated HCl
MeOH, 60 o C, N2

OH
OH

O

MOM
O

Boc

H
N

N
H
too complicated

O
BBr3 in DCM

HN
O

R=

O

H 2N

O
N
H

OH

O

N
S

DCM, -100o C
O
BCl3 in DCM

O

DCM, -100o C

BF3 in DCM
DCM, -100o C

Scheme 3. Synthetic routes of final deprotected compound 13.
Although compound 11 was successfully synthesized, there were many complications for
the deprotection of MOM- and Boc- groups, as shown in Scheme 3. The molecule was very
fragile to harsh conditions. The trifluoroacetic acid (TFA), pKa of ~0.3, was first used to remove
the MOM- and Boc- groups, which was unsuccessful. At 10% TFA in DCM, only the Bocgroup was cleaved and MOM-group was intact. At 50% TFA in DCM, the products were too
complicated to separate and the residue, left after the reaction, had overlapping peaks on the
HPLC. Apparently, TFA was not a good reagent for the removal of the MOM- and Boc- groups.
Thus, other methods were considered.
It was reported that trace amount of concentrated HCl in MeOH at 62 ºC for 15 minutes
can cleave the MOM-group13. There was also an experiment that reported 4 M HCl in MeOH at
room temperature for 30 minutes can cleave the Boc-group14.

In addition, water in the

R
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concentrated HCl has been used to prevent double bond isomerization that occur under
anhydrous acidic condition15. Therefore, the second route was to use a trace concentrated HCl in
MeOH at 60 ºC for 15 minutes. Unfortunately, this experiment was not successful either.
KCN-1 was found to be sensitive in acidic environment and decomposed easily based on 1H
NMR.
OMOM

O

O

N S
O

KCN-1

O

O

BCl3, BBr3, or BF3 in DCM
Boc

NH

O

N S R

O

O

OH

O

O

DCM, -100oC

Ester Linker

O

O
NH 2

P2

P1

Scheme 4. Test model reactions of boron trihalides in DCM under -100 ºC.
Since HCl was too acidic for compound 11, the search for better reagents led to boron
trihalides. Some boron trihalides, such as boron trichloride (BCl3), boron tribromide (BBr3), and
boron trifluoride (BF3) were considered to be good candidates. Test model reactions were
conducted to determine the effectiveness of the boron trihalides. These tests consisted of one
equivalent of KCN-1, one equivalent of photocleavable linker derivative ester, and two
equivalents of the boron trihalides in DCM under -100 ºC, as shown in Scheme 4. The products
were the deprotected ester linker (P1) and the decomposed KCN-1 (P2). The R in P2 meant that
portion of KCN-1 had decomposed. After the reaction was completed, the product was separated
by flash chromatography and analyzed by 1H NMR.
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Figure 2.1: Test model reactions monitored by TLC.
Thin layer chromatography (TLC) was used to monitor the overall reaction as shown in
Figure 2.1. For boron trichloride, the ester linker was deprotected completely within 30 minutes
and KCN-1 decomposed slightly. However, for boron tribromide, the ester linker was not fully
deprotected and KCN-1 decomposed entirely at 15 minutes. Boron trifluoride was even worse
than BBr3. For BF3, KCN-1 had decomposed at 10 minutes. Based on these results, BCl3 was a
better candidate because BF3 and BBr3 are too acidic for the reaction. A milligram test of
compound 11 will be used to determine the reactivity of BCl3 soon. Hopefully, the deprotection
of compound 11 will be resolved as expected.
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3.

CONCLUSION

Compound 11 was synthesized in 10 steps with 3.6% overall yield for now, but the step
of deprotection seems more difficult than expected. Searching for an effective deprotecting
reagent for compound 11 is underway now. If an effective reagent cannot be found in the near
future, the design of the research has to be modified to replace the MOM- group with a different
protecting group. Hopefully, the deprotection of compound 11 will be resolved soon. Then this
research will be complete once compound 11 is deprotected and attached to the immobilized
bead. After the small molecule is completely synthesized, it will be sent off for affinity labeling
and analysis of the mass of the peptide sequence to determine the binding target of KCN-1.
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4.
4.1

EXPERIMENTAL

General Methods
NMR spectra were recorded at 400 MHz for 1H and 100 MHz for

13

C on a Bruker 400

Avance instrument. Chemical shifts (δ values) and coupling constants (J values) are reported in
parts per million (ppm) and hertz (Hz), respectively, using TMS (1H NMR) or deuterated solvent
(13C NMR) as the internal standard (s = singlet, d =doublet, dd = double doublet, t = triplet, q =
quartet, m = multiplet, br = broad). Unless otherwise noted, all reagents and the authentic
samples were purchased from commercial sources and were used without further purification.
Flash chromatography was carried out on flash silica gel (Sorbent 230–400 mesh). TLC analysis
was conducted on silica gel plates (Sorbent Silica G UV254). Mass spectroscopy was recorded
on API 3200 LC/MS/MS system.
4.2

Photocleavable Linker
3-Hydroxy-4-iodobenzoic acid 2. To a mixture of a solution of 3-hydroxybenzoic acid

1 (13.8 g, 0.10 mol) in concentrated aqueous ammonia was slowly added a mixture of I2
(23.4 g, 0.09 mol) and potassium iodide (18.6 g, 0.11 mol) in de-ionized water (100 mL) (to
prevent from generating NI3). The reaction mixture was stirred at room temperature for 40
minutes, and then acidified by concentrated HCl (180 mL). The precipitate was collected by
filtration. The filtrate was extracted with EtOAc (250 mL × 2). The precipitate was combined
with the organic layer and the EtOAc was removed under reduced pressure.

The crude

compound was purified by recrystalization (H2O/MeOH=5/1) to yield white crystal (9.24 g,
35%). 1H NMR (MeOD): δ 7.79 (d, J=8.0 Hz, 1H), 7.46 (d, J=2.0 Hz, 1H), 7.22 (dd, J=8.0, 2.0
Hz, 1H).

13

C NMR (MeOD): δ 169.5, 158.3, 140.6, 133.4, 123.1, 116.3, 93.4. ESI-MS (−):

Calcd for C7H5IO3: 263.93 m/z. Found: 262.9 m/z [M−H]−.
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5-(Hydroxymethyl)-2-iodophenol 3. Under N2 atmosphere at 0 ºC, to a solution of
3-hydroxy-4-iodobenzoic acid 2 (9.30 g, 0.04 mol) in anhydrous THF (100 mL) was slowly
added borane in THF (70.0 mL, 0.07 mol). The reaction mixture was stirred at room temperature
overnight. Then reaction mixture was quenched with 2 M Na2CO3 (10 mL). The aqueous
solution was extracted with Et2O (20 mL × 2). The organic layer was dried with Na2SO4 and
concentrated under reduced pressure.

The crude compound was purified by flash

chromatography on silica gel (hexane/EtOAc=5/1) to yield pale yellow crystal (8.60 g, 86%). 1H
NMR (CD3OD): δ 7.61 (d, J=8.0 Hz, 1H), 6.86 (s, 1H), 6.59 (dd, J=8.0 Hz, 1H), 4.50 (s, 2H).
13

C NMR (CD3OD): δ 158.2, 145.0, 140.3, 120.9, 114.4, 82.9, 64.6. ESI-MS (−): Calcd for

C7H7IO2: 249.95 m/z. Found: 248.4 m/z [M−H]−.
(4-Iodo-3-(methoxymethoxy)phenyl)methanol 4. To a mixture of 5-(hydroxymethyl)2-iodophenol 3 (5.00 g, 0.02 mol) and K2CO3 (5.60 g, 0.04 mol) in acetone (4 mL) was added
methoxymethyl chloride (4 mL, 0.53 mol) and the resulting mixture was stirred at room
temperature overnight. The reaction mixture was filtered and washed with acetone. The filtrate
was concentrated under reduced pressure. The residue was added H2O (20 mL) and EtOAc
(20 mL). Then the aqueous solution was further extracted with EtOAc (20 mL × 2). The organic
layer was dried with Na2SO4 and concentrated under reduced pressure. The crude was purified
by flash chromatography on silica gel (hexane/EtOAc=7/1 (200 mL), 2/1 (400 mL), 3/2 (200
mL)) to yield yellow liquid (1.94 g, yield 33%). ESI-MS (−): Calcd for C9H11IO3: 293.98 m/z.
Found: 292.9 m/z [M−H]−.
4-(Azidomethyl)-1-iodo-2-(methoxymethoxy)benzene 5. Under N2 atmosphere at 0 ºC,
to a solution of (4-iodo-3-(methoxymethoxy)phenyl) methanol 4 (104 mg, 0.35 mmol) in
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anhydrous THF (5 mL) was added diphenyl phosphorazidate (DPPA) (91 µL, 0.42 mmol) and
the resulting mixture was stirred for ten minutes. Then diazabicycloundecene (DBU) (64 µL,
0.42 mmol) was added into the solution. The reaction was warmed to room temperature and
stirred overnight under N2. Then reaction mixture was concentrated under reduced pressure.
The residue was added H2O (10 mL) and EtOAc (10 mL). The aqueous solution was further
extracted with EtOAc (10 mL × 2). The organic layer was dried with Na2SO4 and concentrated
under reduced pressure.

The crude was purified by flash chromatography on silica gel

(hexane/EtOAc=20/1) to yield yellow liquid (78 mg, yield 70%). 1H NMR (CDCl3): δ 7.74 (d,
J=8.0 Hz, 1H), 7.01 (d, J=2.0 Hz, 1H), 6.71 (dd, J=8.0, 2.0 Hz, 1H), 5.23 (s, 2H), 4.27 (s, 2H),
3.49 (s, 3H).
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C NMR (CDCl3): δ 156.3, 139.7, 137.3, 123.2, 114.4, 94.9, 86.8, 56.5, 54.2.

ESI-MS (−): Calcd for C9H10IN3O2: 318.98 m/z. Found: 317.7 m/z [M−H]−.
(4-Iodo-3-(methoxymethoxy)phenyl)methanamine

6.

To

a

solution

of

4-

(azidomethyl)-1-iodo-2-(methoxymethoxy)benzene 5 (1.60 g, 4.9 mmol) and triphenylphosphine
(PPh3) (2.60 g, 9.9 mmol) in THF (49 mL, 10 mL per mmol) was added de-ionized water (2 mL,
0.04 mL per mmol) and the reaction was stirred at room temperature overnight. The reaction
mixture was concentrated under reduced pressure. The residue was added brine (10 mL) and
EtOAc (10 mL). The aqueous solution was further extracted with EtOAc (15 mL × 2).

The

organic layer was dried with Na2SO4 and concentrated under reduced pressure. The crude was
purified by flash chromatography on silica gel (hexane/EtOAc=20/1 (200 mL) to elute out PPh3,
then pure EtOAc (100 mL) once the triphenylphosphine oxide came out, finally pure MeOH
(300 mL) for the product) to yield yellow liquid (1.35 g, yield 94%). ESI-MS (+): Calcd for
C9H12INO2: 292.99 m/z. Found: 293.9 m/z [M+H]+.
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tert-Butyl 4-iodo-3-(methoxymethoxy)benzylcarbamate 7. To a solution of (4-iodo-3(methoxymethoxy)phenyl)methanamine 6 (25 mg, 0.08 mmol) and di-tert-butyl dicarbonate (23
mg, 0.10 mmol) in MeOH (5 mL) was added triethylamine (14 µL, 0.10 mmol) and the resulting
mixture was stirred at room temperature overnight. The reaction mixture was concentrated under
reduced pressure.

The crude was purified by flash chromatography on silica gel

(hexane/EtOAc=10/1) to yield yellowish white crystal (17 mg, yield 53%). 1H NMR (D2O): δ
7.71 (d, J=8.0 Hz, 1H), 6.98 (d, J=2.0 Hz, 1H), 6.71 (d, J=8.0 Hz, 1H), 5.23 (s, 2H), 4.89 (s, 1H),
4.25 (d, J=8 Hz, 2H), 3.51 (s, 3H), 1.46 (s, 9H).

13

C NMR (D2O): δ 156.4, 156.1, 141.4, 139.7,

122.8, 114.1, 95.2, 85.7, 79.9, 56.7, 44.5, 28.6, 27.6. ESI-MS (+): Calcd for C14H20INO4:
393.04 m/z. Found: 394.4 m/z [M+H]+.
(E)-3-(4-((tert-Butoxy carbonylamino) methyl)-2- (methoxymethoxy) phenyl) acrylic
acid 8. Under N2 atmosphere at room temperature, to a mixture of (t-Bu)4N+ Br

(188 mg,

0.58 mmol), Pd(OAc)2 (5.4 mg, 0.02 mmol), and K2CO3 (642 mg, 4.7 mmol) was added a
solution of tert-butyl 4-iodo-3-(methoxymethoxy)benzylcarbamate 7 (183 mg, 0.47 mmol) in
DMF (2 mL). Then acrylic acid (48 µL, 0.70 mmol) was added into the mixture. The reaction
mixture was heated to 60o C and stirred overnight. Then the reaction mixture was cooled to
room temperature. Cold H2O (5 mL) and 1 M HCl (1 mL) were added to the mixture. The
reaction mixture was added brine (10 mL) and EtOAc (15 mL). The aqueous solution was
further extracted with EtOAc (15 mL × 2).

The organic layer was dried with MgSO4 and

concentrated under reduced pressure. The crude was purified by flash chromatography on silica
gel (hexane/EtOAc=20/1 (200 mL), 4/1 (400 mL), 1/1 (200 mL)) to yield yellow crystal (81 mg,
51%). 1H NMR (D2O): δ 8.09 (d, J=16.0 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 7.08 (s, 1H), 6.95 (d,
J=8.0 Hz, 1H), 6.51 (d, J=16 Hz, 1H), 5.26 (s, 2H), 4.96 (s, 1H), 4.31 (d, J=8 Hz, 2H), 3.51 (s,

21

3H), 1.47 (s, 9H).

13

C NMR (D2O): δ 172.5, 156.6, 156.2, 143.8, 141.9, 129.2, 123.0, 120.9,

117.9, 113.8, 94.8, 80.0, 56.6, 44.7, 28.6. ESI-MS (−): Calcd for C17H23NO6: 337.15 m/z.
Found: 336.2 m/z [M−H]−.
(E)-2,5-Dioxopyrrolidin-1-yl 3-(4-((tert-butoxycarbonylamino)methyl)-2-(methoxy
methoxy) phenyl)acrylate 9. Under N2 atmosphere at room temperature, to a solution of (E)-3(4-((tert-butoxycarbonylamino)methyl)-2-(methoxymethoxy)phenyl)acrylic acid 8 (70 mg,
0.21 mmol) and EDCI (39 mg, 0.21 mmol) in anhydrous DCM (3 mL) was added
N-hydroxysuccinimide (24 mg, 0.21 mmol) dissolved in anhydrous DCM (1 mL) and the
resulting mixture was stirred overnight. The reaction mixture was concentrated under reduced
pressure. The residue was added brine (10 mL) and EtOAc (10 mL). The aqueous solution was
further extracted with EtOAc (10 mL × 2).

The organic layer was dried in MgSO4 and

concentrated under reduced pressure. The crude was purified by flash chromatography on silica
gel (hexane/EtOAc=4/1 (100 mL), 3/1 (400 mL), and 1/1 (300 mL)) to yield colorless crystals
(57 mg, 63%). ESI-MS (+): Calcd for C21H26N2O8: 434.17 m/z. Found: 435.1 m/z [M+H]+.
(E)-2-(3-(4-((tert-Butoxycarbonylamino)methyl)-2-(methoxymethoxy) phenyl) acryl
amido ) -3-(3,4-dihydroxyphenyl)propanoic acid 10. To a solution of (E)-2,5-dioxopyrrolidin1-yl 3-(4-((tert-butoxycarbonylamino)methyl)-2-(methoxymethoxy)phenyl) acrylate 9 (57 mg,
0.13 mmol) and (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid (L-DOPA) (22 mg, 0.11
mmol) in anhydrous DMF (1.5 mL) was added triethyl amine (NEt3) (18 µL, 0.13 mmol) and the
reaction was stirred at room temperature overnight. Then the pH was adjusted from 8 to 3 by
adding 1 M HCl (~10 mL) to the mixture. The reaction mixture was added brine (10 mL) and
EtOAc (15 mL). The aqueous solution was further extracted with EtOAc (10 mL × 2). The
organic layer was dried in MgSO4 and concentrated under reduced pressure. The crude was
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purified by flash chromatography on silica gel (DCM/MeOH=14/1 (200 mL), 10/1 (400 mL),
and 5/1 (100 mL)) to yield yellow crystals (46 mg, 68%). 1H NMR (MeOD): δ 7.82 (d, J=16
Hz, 1H), 7.47 (d, J=8 Hz, 1H), 7.07 (s, 1H), 6.89 (d, J=8 Hz, 1H), 6.70 (d, J=16 Hz, 1H), 6.67 (s,
1H), 6.66 (d, J=8 Hz, 1H), 6.57 (d, J=8 Hz, 1H), 5.22 (s, 2H), 4.71 (dd, J=7.2, 5.6 Hz, 1H), 4.19
(s, 2H), 3.43 (s, 3H), 3.10 (dd, J=14, 6 Hz, 1H), 2.91 (dd, J=14, 6 Hz, 1H), 1.45 (s, 9H).
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C

NMR (MeOD): δ 175.9, 168.8, 158.7, 157.3, 146.2, 145.2, 144.6, 137.0, 130.1, 129.3, 124.4,
121.9, 121.8, 121.6, 117.5, 116.4, 114.6, 95.8, 80.4, 56.9, 56.1, 44.9, 38.2, 28.9. Calcd for
C26H32N2O9: 516.21 m/z. Found: 515.1 m/z [M−H]−.
(E)-tert-Butyl 4-(3-(3-(3,4-dihydroxyphenyl)-1-(4-(4-(N-((2,2-dimethyl-2H-chromen6-yl)methyl)-N-phenylsulfamoyl)-2-methoxyphenoxy)butylamino)-1-oxopropan-2ylamino)-3-oxoprop-1-enyl)-3-(methoxymethoxy)benzylcarbamate 11. Under N2 atmosphere
at room temperature, to a solution of (E)-2-(3-(4-((tert-butoxycarbonylamino) methyl)-2(methoxy methoxy)phenyl) acrylamido)-3-(3,4-dihydroxy phenyl) propanoic acid 10 (21 mg,
0.04 mmol), EDCI hydrochloride (8, 0.04 mmol), and HOBt (5 mg, 0.04 mmol) in anhydrous
DCM (2 mL) was added KCN-1 amine 12d (20 mg, 0.04 mmol) dissolved in anhydrous DCM
(0.2 mL) by a syringe. Two equivalent of anhydrous DCM (0.2 mL) was used to wash the vial
and syringe used to add the KCN-1 amine. The reaction was stirred at room temperature
overnight. The reaction mixture was concentrated under reduced pressure. The crude was
purified by flash chromatography on silica gel (DCM/MeOH=20/1 (100 mL), 10/1 (100 mL), 5/1
(150 mL), pure MeOH (50 mL)) to yield white crystal (19 mg, 47%). 1H NMR (MeOD): δ 7.85
(d, J=16 Hz, 1H), 7.51 (d, J=8 Hz, 1H), 7.29 (m, 2H), 7.23 (m, 3H), 7.08 (m, 3H), 7.00 (m, 2H),
6.93 (m, 2H), 6.82 (m, 1H), 6.69 (m, 2H), 6.60 (m, 1H), 6.53 (m, 1H), 6.22 (d, J=10 Hz, 1H),
5.62 (d, J=10 Hz, 1H), 5.25 (s, 3H), 4.61 (s, 3H), 4.21 (s, 2H), 4.02 (t, 2H), 3.69 (s, 3H), 3.44 (s,
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3H), 3.14 (dd, J=12, 6 Hz, 1H), 2.96 (dd, J=12, 6 Hz, 1H), 2.86 (dd, J=12, 6 Hz, 1H), 1.65 (m,
5H).
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C NMR (MeOD): δ 173.7, 168.8, 157.5, 153.9, 150.6, 146.4, 145.4, 140.6, 137.3, 132.2,

131.1, 130.6, 129.9, 129.1, 127.9, 124.5, 123.2, 122.6, 121.75, 117.6, 117.1, 116.6, 114.7, 113.2,
111.9, 95.9, 80.5, 77.5, 70.0, 57.1, 56.7, 55.1, 49.8, 48.5, 45.0, 40.0, 38.9, 30.9, 28.9, 28.3, 27.3,
27.0. ESI-MS (−): Calcd for C55H64N4O13S: 1020.42 m/z. Found: 1019.8 m/z [M−H]−.
4.3

KCN-1 AMINE (12d)
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-4-hydroxy-3-methoxy-N-phenyl

benzene sulfonamide 12b. Under N2 atmosphere at 150 ºC, to a mixture of K2CO3 (149 mg,
1.07 mmol) in N-Methyl-2-pyrrolidone (NMP) (2 mL) was added thiophenol (PhSH) (0.11 mL,
1.07 mmol) and the reaction mixture was stirred for 15 minutes. Then a solution of N-((2,2dimethyl-2H-chromen-6-yl)methyl)-3,4-dimethoxy-N-phenylbenzene-sulfonamide 12a (100 mg,
0.21 mmol) in NMP (1 mL) was added into the reaction mixture. The reaction was stirred for 5
minutes (no longer than 5 minutes) and immediately poured into cold de-ionized H2O (25 mL).
The aqueous solution was extracted with EtOAc (50 mL × 4). Brine (~10 mL) was added as
needed for better separation. The organic layer was washed with de-ionized water (20 mL × 6)
to get rid of most of NMP. The organic layer was dried in MgSO4 and concentrated under
reduced pressure.

The crude was purified by flash chromatography on silica gel

(DCM/EtOAc=50/1 (500 mL), 30/1 (200 mL)) to yield white crystal (57 mg, 60%). ESI-MS (−):
Calcd for C25H25NO5S: 451.15 m/z. Found: 450.1 m/z [M−H]−.
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-4-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-3methoxy-N-phenylbenzenesulfonamide 12c. Under N2 atmosphere at 50 º C, a solution of 2(4-bromobutyl) isoindoline-1,3-dione (90 mg, 0.32 mmol), N-((2,2-dimethyl-2H-chromen-6yl)methyl)-4-hydroxy-3-methoxy-N-phenyl benzenesulfonamide 12b (130 mg, 0.29 mmol), and
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K2CO3 (44 mg, 0.32 mmol) in (DMF) (2 mL) was stirred overnight. The reaction mixture was
added de-ionized H2O (20 mL) and EtOAc (20 mL). The aqueous solution was further extracted
with EtOAc (100 mL × 2). The organic layer was dried in MgSO4 and concentrated under
reduced pressure.

The crude was purified by flash chromatography on silica gel

(DCM/EtOAc=50/1) to yield colorless solid (89 mg, 47%). 1H NMR (MeOD): δ 7.75 (m, 2H),
7.65 (m, 2H), 7.32 (m, 1H), 7.27 (m, 3H), 6.99 (m, 2H), 6.97 (m, 4H), 6.59 (d, J=8 Hz, 1H), 6.21
(d, J=8 Hz, 1 H), 5.55 (d, J=8 Hz, 1H), 4.59 (s, 2H), 4.12 (m, 3H), 3.88 (m, 2H), 3.73 (s, 3H),
2.04 (s, 1H), 1.92 (s, 4H), 1.27 (s, 6H), 1.24 (m, 2H). ESI-MS (+): Calcd for C37H36N2O7S:
652.22 m/z. Found: 653.3 m/z [M+H]+.
4-(4-Aminobutoxy)-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-3-methoxy-N-phenyl
benzenesulfonamide (KCN-1 amine) 12d. Under N2 atmosphere at refluxed, to a solution of
N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-4-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-3-methoxyN-phenylbenzenesulfonamide 12c (48 mg, 0.07 mmol) in EtOH/DCM (75/25) (3 mL) was added
hydrazine monohydrate (H2N-NH2·H2O) (7.1 µL, 0.15 mmol) and the resulting mixture was
stirred overnight. The reaction mixture was concentrated under reduced pressure and then
vacuum filtrate with DCM. The filtrate organic layer was concentrated under reduced pressure.
The crude was purified by flash chromatography on silica gel (DCM/MeOH=20/1 (200 mL),
10/1 (500 mL), 5/1 (300 mL)) to yield colorless solid (20 mg, 55%). 1H NMR (MeOD): δ 7.29
(m, 1H), 7.27 (m, 3H), 6.98 (m, 2H), 6.94 (m, 1H), 6.91 (m, 2H), 6.85 (m, 1H), 6.57 (d, J=8 Hz,
1H), 6.20 (d, J=8 Hz, 1H), 5.55 (d, J=8 Hz, 1H), 4.60 (s, 2H), 4.05 (t, 2H), 3.69 (s, 3H), 2.74 (t,
2H), 1.87 (m, 5H), 1.70 (s, 3H), 1.61 (m, 2H), 1.35 (s, 6H).
C29H34N2O5S: 522.22 m/z. Found: 523.3 m/z [M+H]+.

ESI-MS (+):

Calcd for
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